

1 **Supplementary Appendix**

2 **Table of Contents**

3 List of Investigators ..... 2

4 Supplementary Methods..... 3

5 Supplementary Figures..... 7

6 Supplementary Tables..... 21

7 Supplementary References ..... 24

8

9

10 **List of Investigators**

11

12 Annika Rössler<sup>1,\*</sup>

13 Antonia Netzl<sup>2,\*</sup>

14 Ludwig Knabl<sup>3</sup>

15 Helena Schäfer<sup>1</sup>

16 Samuel H. Wilks<sup>2</sup>

17 David Bante<sup>1</sup>

18 Barbara Falkensammer<sup>1</sup>

19 Wegene Borena<sup>1</sup>

20 Dorothee von Laer<sup>1</sup>

21 Derek Smith<sup>2,#</sup>

22 Janine Kimpel<sup>1,#</sup>

23

24 <sup>1</sup>Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of  
25 Innsbruck, Peter-Mayr-Str. 4b, 6020 Innsbruck, Austria

26 <sup>2</sup>University of Cambridge, Center for Pathogen Evolution, Department of Zoology, Cambridge, UK

27 <sup>3</sup>Tyrolpath Obrist Brunhuber GmbH, Hauptplatz 4, 6511, Zams, Austria

28

29 \*Contributed equally

30 #Corresponding authors:

31 Derek Smith (djs200@cam.ac.uk) and Janine Kimpel (Janine.Kimpel@i-med.ac.at)

32

33

## 34 **Supplementary Methods**

35

### 36 *Patient Characteristics*

37 Patients were divided into three groups depending on their numbers of exposure to  
38 infection/vaccination. Single exposure was defined as unvaccinated with a single infection (n=10  
39 infected during first wave (wild type), n=10 alpha, n=8 beta, n=7 delta, n=18 BA.1 omicron, and n=12  
40 BA.2 omicron. Double exposure was defined as either unvaccinated individuals with two subsequent  
41 infections (n=15 with pre-omicron infection followed by BA.1 re-infection and n=3 with pre-omicron  
42 infection followed by BA.2 re-infection) or two vaccine doses without any history of infection (two  
43 homologous doses of mRNA-1273 (n=10), ChAdOx-S1 (n=10) or BNT162b2 (n=11) respectively or  
44 heterologous vaccination with ChAdOX-S1 as first and BNT162b2 as second dose (n=10)). Three or  
45 more exposures were defined as vaccinated individuals with breakthrough infections (n=6 with delta  
46 breakthrough after two doses of ChAdOx-S1, n=22 with delta breakthrough after two doses of  
47 BNT162b2, n=14 with two or three vaccine doses and BA.1 omicron breakthrough, and n=8 with two  
48 or three vaccine doses and BA.2 omicron breakthrough) or vaccinated individuals with a previous pre-  
49 omicron breakthrough followed by a BA.1 omicron breakthrough (n=11).

50

### 51 *Map Diagnostics*

52 Map diagnostic tools were used to assess the quality of the antigenic map with P.1.1 reactivity adjusted  
53 by -1 on the  $\log_2$  scale (Figure 2, Supplementary Figure S2).

54

### 55 *Map Dimensionality*

56 First, a dimensionality test was performed with *Racmacs*'<sup>1</sup> *dimensionTestMap* function in dimensions  
57 1 to 5 with a test proportion of 0.1, the minimum column basis set to "none", the fixed column bases  
58 of the current map, and 100 replicates per dimension with 1000 optimizations per replicate. The Root  
59 Mean Square Error RMSE between measured and predicted titers was used to judge which  
60 dimensionality best represents the antigenic relationships of the titer data. Figure S3 shows that the  
61 error between predicted and measured titers is smallest in two dimensions, indicating that the titer  
62 data is best represented by a 2D map.

63

### 64 *Correlation of fitted and measured titers*

65 Next, the correlation of fitted and measured titers of the map was assessed by converting map  
66 distances into  $\log_2$  titers. As one antigenic unit in the map corresponds to one two-fold dilution in the  
67 neutralization assay, subtracting the Euclidean distance for each serum-antigen pair from the  
68 maximum  $\log_2$  titer of the specific serum gives  $\log_2$  titers.

69 Doing this for each serum group revealed good correlation of measured and fitted  $\log_2$  titers (Figure  
70 S4). In the omicron convalescent serum groups, measured titers exceeded fitted titers slightly. A large  
71 number of below detectable titers, however, impairs the accurate positioning of a serum and explains  
72 the larger difference between measured and fitted titers in the omicron convalescent compared to  
73 other serum groups.

74

75 *Map robustness*

76 Bootstrapping on sera and antigens was performed to determine how robust the map is to  
77 measurement noise and the exclusion of samples and antigen variants. *Racmacs'*<sup>1</sup> *bootstrapMap*  
78 function with the “noisy” method was used to simulate measurement noise, doing 1000 repeats and  
79 100 optimizations per repeat, bootstrapping both sera and antigens with normally distributed  
80 measurement noise with a standard deviation of 0.7 added to either the titer, the antigen or both  
81 (Figure S5). The same function and optimization routine was used to test the impact of serum and  
82 antigen exclusion on the map, using the “resample” method with antigen and titer noise standard  
83 deviation of 0.7, and resampling only antigens, sera or resampling both (Figure S6). To test the  
84 exclusion of entire serum groups (Figure S7) or antigen variants (Figure S8), maps were constructed  
85 excluding the specific sera or variant with 500 optimizations per map and the minimum column basis  
86 set to “none”.

87 Adding noise to antigen reactivity adds noise to all titers measured against the specific antigen,  
88 whereas titer noise adds noise to a single measurement. The effects of which are shown in Figure S5.  
89 The variants' positions were robust to titer noise (Figure S5B). The positions of non-omicron variants  
90 varied by one to two antigenic units when adding noise to antigenic reactivity (Figure S5 A, C). Antigen  
91 noise resulted in hemispheric of BA.1 omicron, referring to two distinct optima for the variant's  
92 position. The big effect on variant position by some noise can be understood if the added noise moves  
93 an originally detectable titer below the detection threshold, or vice-versa. In case of the two omicron  
94 sub-lineages, many titers were at the border or below detectable, hence adding artificial measurement  
95 noise affected the positioning of these variants more than the other variants.

96 This can also be seen in Figure S6, where 1000 optimization runs were performed in which both  
97 antigens and sera were randomly resampled with replacement (Figure S6A), only antigen variants were  
98 resampled (Figure S6B) or individual serum samples were randomly sampled with replacement (Figure  
99 S6C). Resampling variants had little effect on non-omicron variant positioning, but again two different  
100 optima were found for BA.1 and BA.2 omicron. While serum bootstrapping had little effect on both  
101 variants and sera (Figure S6C), variant bootstrapping demonstrated the uncertainty of BA.1 and BA.2  
102 omicron convalescent sera positioning (Fig. S6 B), which had detectable titers against their root variant  
103 but very low to non-detectable titers against other variants.

104 However, the distance of BA.1 and BA.2 omicron from vaccine sera and to each other remained stable.

105 To investigate which serum groups or variants had a particularly large impact on map topology, maps  
106 excluding single serum groups (Figure S7) or antigen variants (Figure S8) were constructed. Excluding  
107 BA.1 omicron conv. sera resulted in the effect on BA.1 and BA.2 omicron positions we observed when  
108 adding noise or resampling variants in map construction. Removal of other serum groups had no effect  
109 on variant positions.

110 Excluding the D614G and beta variant had a similar effect and moved both omicron variants to a  
111 second optimal position (Figure S8).

112

113 *Map cross-validation*

114 For cross validation, *Racmacs'*<sup>1</sup> *dimensionTestMap* function was employed to optimize maps in 2  
115 dimensions with a test proportion of 0.1. 1000 replicates and 500 optimizations per replicate were  
116 performed and the difference between measured and predicted titer calculated on the log<sub>2</sub> scale.

117 Briefly, 1000 optimizations runs were performed in which only 90% of titers were used for map  
118 construction and the remaining 10% predicted by subtracting the Euclidean map distance for each  
119 serum-antigen pair from the maximum  $\log_2$  titer of the specific serum. The mean difference between  
120 measured and predicted  $\log_2$  titer was less one two-fold for detectable titers (Figure S9). However, this  
121 differed largely across serum groups and antigen variants (Figure S10). The variability of BA.1 and BA.2  
122 omicron conv. sera positions, and BA.1 and BA.2 omicron variant positions seen in the bootstrap map  
123 resulted in much lower predicted than measured titers for these variants in the specific serum groups.  
124 As before, if detectable titers against these variants were excluded from the map creation, their  
125 position became inaccurate and hence sera with only detectable titers against BA.1 or BA.2 omicron,  
126 which was true for the majority of BA.1 and BA.2 omicron conv. sera, could not be positioned either.

127

### 128 *Individual antibody landscapes*


129 Antibody landscapes<sup>2</sup> were constructed as described in *Materials & Methods*. With the map shown in  
130 Figure 2 serving as base plane, antibody levels for each serum were plotted in a third dimension and a  
131 continuous surface fitted to the available titer data. The reactivity profile of serum groups exposed to  
132 a single variant, such as the convalescent and double vaccinated serum groups (Figure S11 A-J), was  
133 assumed to adopt a cone like shape, with the highest point at the specific serum coordinate and a  
134 constant decrease across antigenic space of one two-fold per antigenic unit.<sup>3</sup> This assumption does not  
135 apply to serum groups exposed to more than one variant, as high titers against both encountered  
136 variants are expected. For these groups (Figure S11 K-Q), each serum's coordinates were fitted to  
137 optimize the serum's position in the map shown in Figure 2 and the surface's slope was fitted per  
138 serum group, as the decrease of reactivity was assumed to be the same for individuals with the same  
139 exposure history. The GMT landscapes show the average of all individual antibody landscapes.

140 The vaccine landscapes (Figure S11 A-D) were the most homogeneous in terms of titer magnitudes  
141 within the serum group. Further, the different vaccine regiments elicited landscapes similar to each  
142 other. The individual antibody profiles of most most convalescent groups were homogenous. With the  
143 exception of one delta serum with high P.1.1 titers and two BA.2 conv. sera, all had highest titers  
144 against their non-homologous variant. Antibody profiles such as these could be due to unknown prior  
145 infections. The specific delta sample, however, was a PCR-confirmed first infection, suggesting a  
146 different reason for the high titer against P.1.1. To investigate potential prior infection of the two cross-  
147 reactive BA.2 omicron conv. samples, maps were created without these two sera and antibody  
148 landscapes fitted to their titers (Figure S12). The two sera did not impact the variant positions in the  
149 map (Figure S12 A-C). Their antibody profiles, however, looked more similar to BA.2 omicron  
150 breakthrough infections (sample G780) or reinfections (sample G776) than to BA.2 omicron first  
151 infections (Figure S12 D). As the map without those two sera did not differ from the map including the  
152 sera, the general conclusion of BA.2 omicron being positioned between pre-omicron variants and BA.1  
153 omicron did not change.

154 The antibody landscapes after delta breakthrough were similar in both magnitude and shape  
155 independent of Astra Zeneca or Pfizer vaccination (Figure S11 K-L), and were further comparable to  
156 BA.1 and BA.2 omicron breakthrough infections. Breakthrough landscapes after either omicron sub-  
157 lineage infection or vaccinated with prior infection and BA.1 omicron breakthrough were almost  
158 indistinguishable both in titer magnitudes and landscape slope (Figure S11 M-P). All multi-exposure  
159 landscapes, including BA.2 omicron reinfected landscapes (Figure S11 Q), exhibited a broad reactivity  
160 profile, suggesting high degrees of cross-reactivity and good protection against variants within the  
161 current mapped antigenic space.

162 The largest variation of individual landscapes was found in the BA.1 omicron breakthrough and  
163 reinfected serum groups (Figure S11 M, O). To investigate the impact of number of vaccinations and  
164 variant of prior infection, these two groups were split into subgroups and antibody landscapes were  
165 constructed for each subgroup (Figure S13). This revealed that the landscape shape of double and  
166 triple vaccinated individuals with BA.1 omicron breakthrough infection was almost identical, and the  
167 observed variation was due to generally higher titers after three vaccine doses (Figure S13 A-B). The  
168 shapes of reinfection landscapes, however, differed depending on the first encountered variant (Figure  
169 S13 C-D). Prior infection with D614G resulted in antibody profiles similar to the vaccinated and  
170 infected, and previous infection with vaccination groups, with reactivity peaking in the area of D614G  
171 and slowly decreasing towards the omicron variants. Sera infected with delta followed by BA.1 omicron  
172 had lower titers in the upper area of the map (D614G, alpha, beta), with individual landscapes having  
173 higher BA.1 omicron titers than delta titers, resulting in a landscape shape almost mirroring the D614G  
174 landscape. Only one sample was available with a prior alpha infection, which exhibited very low titers  
175 against BA.1 omicron and much less cross-reactivity than the other BA.1 reinfection landscape.


176



178

179 **Figure S1. Fold change neutralizing antibody titers gamma versus exposed variant.** For each sample,  
 180 the fold change titer in neutralizing antibodies ( $IC_{50}$ ) between gamma and the exposed variant was  
 181 calculated. For first wave convalescent or two dose vaccinated individuals the D614G titers were used  
 182 as exposed variant. Shown are individual samples and geometric mean change as bars. Numbers  
 183 indicate the geometric mean change for each group.

184




185  
 186 **Figure S2. Non-zoomed in version of the antigenic map.** Virus variants are shown as colored circles,  
 187 sera as open squares with the color corresponding to the infecting variant. Vaccine sera are shown in  
 188 grey tones (from dark to light: mRNA-1273/mRNA-1273, BNT162b2/BNT162b2, ChAdOx-  
 189 S1/BNT162b2, ChAdOx-S1/ChAdOx-S1). The alpha + E484K variant is shown as smaller circle due to  
 190 its additional substitution compared to the alpha variant. The x- and y-axis represent antigenic  
 191 distances with one grid square corresponding to one two-fold serum dilution of the neutralization  
 192 titer. The map orientation within x- and y-axis is free as only relative distances can be inferred.

193


194






195  
 196 **Figure S3. Map dimensionality.** **A** Dimensionality test: RMSE between map and measured titers for  
 197 detectable titers in 1 to 5 dimensions. Per dimension, 100 map replicates were constructed from 90%  
 198 of measured titers with 1000 optimizations per replicate. The titers of the remaining 10% were  
 199 predicted in each run and the RMSE calculated by comparing the predicted to the measured titers on  
 200 the  $\log_2$  scale. **B, C** Side and front view of the map optimized in 3 dimensions with arrows pointing to  
 201 the variants' position in the 2D map.

202




203  
 204 **Figure S4. Goodness of map fit per serum group.** The top panels show the correlation of detectable  
 205 measured and fitted titers in the 2D map with P.1.1 reactivity adjustment. Measured P.1.1 titers were  
 206 reduced by one two-fold to match the reactivity adjustment in the map. Map distances were converted  
 207 into  $\log_2$  titers by subtracting the Euclidean distance for each serum-antigen pair from the maximum  
 208  $\log_2$  titer of the specific serum. The bottom panels show the residuals of measured against fitted titers  
 209 on the  $\log_2$  scale, light grey marks pairs with the measured titer below the assay detection threshold.  
 210 The mean and mean-centered standard deviation of differences between fitted and detectable  
 211 measured titers are given in the legend of each bottom row panel. This was done for the serum groups  
 212 used to construct the map: **A** mRNA-1273/mRNA-1273, **B** ChAdOx-S1/ChAdOx-S1, **C** ChAdOx-  
 213 S1/BNT162b2, **D** BNT162b2/BNT162b2, **E** first wave conv., **F** alpha conv., **G** beta conv., **H** delta conv., **I**  
 214 BA.1 omicron conv., **J** BA.2 omicron conv.

215




216  
 217 **Figure S5. Assessing map robustness to measurement uncertainty by bootstrapping.** 1000 bootstrap  
 218 repeats were performed with 100 optimizations per repeat. Normally distributed measurement noise  
 219 with a standard deviation of 0.7 was added to **A** titers and antigen reactivity, **B** only titers, and **C** only  
 220 antigen reactivity. The colored regions mark 68% (one standard deviation) of the positional variation  
 221 for each variant (filled shapes) and sera (open shapes). The colors correspond to the colors used in  
 222 Figure 2.




223  
 224 **Figure S6. Assessing map robustness to the exclusion of measurements by bootstrapping.** 1000  
 225 bootstrap repeats were performed with 100 optimizations per repeat. For each repeat, a random  
 226 subset of titer measurements was taken with replacement. The bootstrapping was performed on **A**  
 227 variants and sera, **B** only variants, and **C** only sera. The colored regions mark 68% (one standard  
 228 deviation) of the positional variation for each variant (filled shapes) and sera (open shapes). The colors  
 229 correspond to the colors used in Figure 2.

230




231  
 232 **Figure S7. Assessing map robustness to the exclusion of sera.** Each serum group was removed and  
 233 the map reoptimized. Arrows point to the position of each variant in the map shown in Figure 2, for  
 234 color correspondence refer to this map. A small arrow length indicates similar variant positions and  
 235 map robustness to the exclusion of the particular serum group. Triangles point to sera positioned  
 236 outside the plotting area. Maps without **A** mRNA-1273/mRNA-1273, **B** ChAdOx-S1/ChAdOx-S1, **C**  
 237 ChAdOx-S1/BNT162b2, **D** BNT162b2/BNT162b2, **E** first wave conv., **F** alpha conv., **G** beta conv., **H** delta  
 238 conv., **I** BA.1 omicron conv., **J** BA.2 omicron conv.

239




240  
 241 **Figure S8. Assessing map robustness to the exclusion of antigen variant.** Each antigen variant was  
 242 removed and the map reoptimized. Arrows point to the position of each variant in the map shown in  
 243 Figure 2, for color correspondence refer to this map. A small arrow length indicates similar variant  
 244 positions and robustness to the exclusion of the particular antigen variant. Triangles point to sera  
 245 positioned outside the plotting area. Maps without **A** D614G, **B** alpha (B.1.1.7), **C** alpha + E484K (B.1.1.7  
 246 + E484K), **D** gamma (P.1.1), **E** beta (B.1.351), **F** delta (B.1.617.2), **G** BA.1 omicron (B.1.1.529+BA.1), **H**  
 247 BA.2 omicron (B.1.1.529+BA.2).

248



249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258

**Figure S9. Map cross-validation residual titers.** 1000 optimization runs were performed with only 90% of measured titers used for map construction by artificially masking 10% of measurements. The missing log<sub>2</sub> titers were predicted by subtracting the Euclidean map distance for each serum-antigen pair from the maximum log<sub>2</sub> titer of the specific serum. The difference between predicted and detectable measured titers on the log<sub>2</sub> scale was calculated, the mean is indicated by the dashed line. The mean and mean-centered standard deviation are given. The upper x-axis limit has been set to 15 for plotting purposes, very few residuals in the BA.1 and BA.2 omicron convalescent groups were larger than 100, due to inaccurate positioning of sera.



259  
260


**Figure S10: Map cross-validation predicted vs. measured titers. Figure caption on next page.**



261 **Figure S10. Map cross-validation predicted vs. measured titers.** 1000 optimization runs were  
262 performed with only 90% of measured titers used for map construction by artificially masking 10% of  
263 measurements. The missing  $\log_2$  titers were predicted by subtracting the Euclidean map distance for  
264 each serum-antigen pair from the maximum  $\log_2$  titer of the specific serum. The detectable measured  
265 over predicted  $\log_2$  titers are shown per serum group and antigen variant. No BA.1 omicron titers were  
266 above the detection threshold in the alpha convalescent and AZ/AZ vaccinated serum groups. The  
267 lower x-axis limit has been set to -10 for plotting purposes, very few residuals in the BA.1 and BA.2  
268 omicron convalescent groups were larger than 100, due to inaccurate positioning of sera. Many  
269 thresholded titers in the original dataset for the omicron variants and in the omicron serum group  
270 resulted in inaccurate predictions if the detectable measurements were masked in map making.

271


272



273


274 **Figure S11. Individual serum antibody landscapes.** The colored surfaces represent the GMT antibody  
 275 landscapes of the different serum groups, the grey transparent surfaces individual serum landscapes.  
 276 Serum reactivity bias was adjusted for GMT calculation as described in (Wilks et al., 2022). The map  
 277 shown in Figure 2 serves as base plane, the z-axis reflects  $\log_2$  titers with each two-fold increase marked  
 278 starting from titer 20. The grey plane at titer 50 serves as reference. The impulses show serum group  
 279 GMTs for each variant. The landscapes are shown for the following serum groups: **A** mRNA-  
 280 1273/mRNA-1273, **B** ChAdOx-S1/ChAdOx-S1, **C** ChAdOx-S1/BNT162b2, **D** BNT162b2/BNT162b2, **E** first  
 281 wave conv., **F** alpha conv., **G** beta conv., **H** delta conv., **I** BA.1 omicron conv., **J** BA.2 omicron conv., **K**  
 282 AZ/AZ + delta breakthrough, **L** BNT/BNT + delta breakthrough, **M** BA.1 omicron breakthrough, **N** BA.2  
 283 omicron breakthrough, **O** BA.1 omicron reinfection, **P** Vaccinated, previous non-omicron infection and  
 284 BA.1 omicron infection, **Q** BA.2 omicron reinfection. Serum coordinates and landscapes for **K-Q** were  
 285 fitted as described in *Materials & Methods*.

286



287  
 288 **Figure S12. Testing effect of cross-reactive BA.2 omicron convalescent sera on map and landscape.**  
 289 **A** Map in Figure 2 shown with two cross-reactive BA.2 convalescent sera (G778, G780) highlighted in  
 290 dark purple. **B** A map was constructed excluding these two sera to test their effect on variant  
 291 positioning. **C** Map in **B** with arrows pointing to the variant's position in map **A**. The small arrows  
 292 indicate that the two cross-reactive samples do not impact BA.2 positioning. **D** GMT Antibody  
 293 landscapes of serum groups which encountered BA.2 omicron (Vacc + BA.2 omicron breakthroughs,  
 294 BA.2 omicron reinf., BA.2 convalescents, (Fig. S11 N, Q, J)) and individual landscapes of the two  
 295 BA.2 convalescent samples with high titers against non-omicron variants (G778, G780). The slope of  
 296 the BA.2 conv. landscape, excluding the two cross-reactive samples, was set to 1, all other slopes and  
 297 serum coordinates were fitted as described in *Material & Methods*. The map shown in panel **B** serves  
 298 as base plane, the z-axis reflects  $\log_2$  titers with each two-fold increase marked starting from titer 20.  
 299 The grey plane at titer 50 serves as reference.

300



301

302 **Figure S13. Variability of BA.1 omicron multi-exposure landscapes.** Individual (transparent) and GMT  
 303 (solid) antibody landscapes for the Vacc + BA.1 omicron (A-B), BA.1 omicron reinf. (C-E) and Vacc +  
 304 BA.1 omicron reinf. (D) after subsetting by number of vaccinations and prior infection (Fig. S11 M, O).  
 305 The map in Figure 2 serves as base plane, the serum coordinates per serum and landscape slopes per  
 306 additional serum group were fitted as described in *Materials & Methods*. Serum reactivity bias was  
 307 adjusted for GMT calculation as described in <sup>3</sup>. The z-axis reflects log<sub>2</sub> titers with each two-fold increase  
 308 marked starting from titer 20. The grey plane at titer 50 serves as reference.

309

310 **Supplementary Tables**

311

312 **Table S1. Patient Characteristics**

Study cohort	number of participants	vaccination -(+/-)	Variant of infection		Mean age (years) ± SD	% female (N)
			first	second		
<b>Single exposure</b>						
First wave convalescent	10	-	ancestral	-	51.6 ± 11.8	60.0 (6)
Alpha convalescent	10	-	alpha	-	49.1 ± 14.3	80.0 (8)
Beta convalescent	8	-	beta	-	79.8 ± 9.5	50.0 (4)
Delta convalescent	7	-	delta	-	27.3 ± 10.3	42.9 (3)
BA.1 convalescent	18	-	BA.1 omicron	-	47.0 ± 17.2	61.1 (11)
BA.2 convalescent	12	-	BA.2 omicron	-	35.8 ± 14.9	50.0 (6)
<b>Double exposure</b>						
BA.1 reinfected	15	-	ancestral (n=5) alpha (n=1) delta (n=9)	BA.1 omicron	35.0 ± 16.9	72.7 (8)
BA.2 reinfected	3	-	ancestral (n=1) delta (n=2)	BA.2 omicron	34.7 ± 6.2	66.7 (2)
mRNA-1273/ mRNA-1273	10	+	-	-	35.4 ± 9.4	60.0 (6)
AZ/AZ	10	+	-	-	37.3 ± 9.3	80.0 (8)
AZ/BNT	10	+	-	-	32.8 ± 4.1	70.0 (7)
BNT/BNT	11	+	-	-	36.1 ± 10.6	63.6 (7)
<b>≥ Triple exposure</b>						
Vacc + BA.1	14	+	omicron (BA.1)	-	36.5 ± 16.8	57.1 (8)
Vacc + BA.2	8	+	omicron (BA.2)	-	32.8 ± 4.1	62.5 (5)
Vacc + BA.1 reinfected	11	+	ancestral (n=4) alpha (n=1) delta (n=6)	BA.1 omicron	36.4 ± 16.8	54.5 (6)
AZ/AZ + delta	6	+	delta	-	30.3 ± 4.6	100.0 (6)
BNT/BNT + delta	22	+	delta	-	50.7 ± 14.4	59.1 (13)

313

314

**Table S2. Statistics for neutralizing antibody titers against indicated variant compared to BA.2 omicron.**

Study cohort	Comparison of BA.2 titers against <sup>§</sup>						
	D614G	Alpha	Alpha + E484K	Beta	Gamma	Delta	BA.1 Omicron
<b>Single exposure</b>							
BA.2 convalescent	ns	*	*	***	*	ns	ns
First wave convalescent	**	*	ns	ns	**	*	ns
<b>Double exposure</b>							
AZ/AZ + delta	ns	ns	***	ns	ns	ns	ns
BNT/BNT + delta	****	****	***	ns	****	***	ns

<sup>§</sup> using non-parametric repeated measures ANOVA with Friedman`s test for multiple comparisons

**Table S3. Representativeness of study.**

Disease, problem, or condition under investigation	BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants
Special considerations related to	
Sex	Female study participants were slightly overrepresented. Seroprevalence through infection in Austria is similar among males and females. <sup>4</sup> A study found equal titers of neutralizing antibodies between male and female participants. <sup>5</sup>
Age	Age was similar in all vaccinated groups; however, in unvaccinated convalescent there were differences. This might influence absolute titers of neutralizing antibodies; however, the ratio between the different variants should not be affected by this.
Ethnicity	Majority of population in Tyrol/Austria is white
Geography	Rates of vaccination and prior infection vary throughout the world. Austria has a vaccination rate of 73.1% (29.04.2022). <sup>6</sup> Seroprevalence in Tyrol has increased in a study among blood donors (healthy adults 18-70 years) from 3.4% in June 2020 to 82.7% in September 2021. <sup>7</sup>
Durability of cross-neutralizing antibodies	Some of the samples from convalescent individuals were collected shortly after infection (2-4 weeks) and therefore conclusions over longevity of these antibodies are limited.
Overall representativeness of this study	Small sample size and retrospective study design are major limitations of the current study. Further studies are needed to include newer omicron sub-variants into the antigenic maps such as BA.4, BA.5 and BA.2.12.1, which are currently rising in South Africa and the USA.

### Supplementary References

1. Wilks S. Racmacs: R Antigenic Cartography Macros. (<https://acorg.github.io/Racmacs/index.html>).
2. Fonville JM, Wilks SH, James SL, et al. Antibody landscapes after influenza virus infection or vaccination. *Science* 2014;346(6212):996-1000. DOI: doi:10.1126/science.1256427.
3. Wilks SH, Mühlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. *bioRxiv* 2022:2022.01.28.477987. DOI: 10.1101/2022.01.28.477987.
4. Knabl L, Mitra T, Kimpel J, et al. High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl. *Commun Med (London)* 2021;1(1):4. (In eng). DOI: 10.1038/s43856-021-00007-1.
5. Pichler D, Baumgartner M, Kimpel J, et al. Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age. *The Journal of infectious diseases* 2021;224(5):764-770. (In eng). DOI: 10.1093/infdis/jiab300.
6. Our World in Data. (<https://ourworldindata.org/covid-vaccinations#what-share-of-the-population-has-completed-the-initial-vaccination-protocol>).
7. Siller A, Seekircher L, Wachter GA, et al. Seroprevalence, waning, and correlates of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: Large-scale study of 35,193 blood donors conducted between June 2020 and September 2021. *medRxiv* 2021:2021.12.27.21268456. DOI: 10.1101/2021.12.27.21268456.